S Saisoong1, S Eiam-Ong, O Hanvivatvong. 1. Inter-Department of Medical Microbiology, Graduate School, Faculty of Medicine,Chulalongkorn University, Bangkok, Thailand.
Abstract
OBJECTIVE: To examine the correlations between antinucleosome antibodies and anti-double-stranded (ds) DNA antibodies, complement (C) 3 and 4 levels, and clinical activities in SLE patients. METHODS: Antinucleosome antibodies and anti-dsDNA antibodies were detected by enzyme-linked immunosorbent assays (ELISA). The levels of C3 and C4 were measured by nephelometry. Clinical activities were determined by SLE Disease Activity Index (SLEDAI). RESULTS: Of 65 SLE patients, the prevalence of antinucleosome antibodies were higher than anti-ds DNA antibodies (52.3 vs 36.9%, respectively, p < 0.05). Similar results were obtained in 45 active SLE patients, 64.4% for antinucleosome antibodies and 46.7% for anti-ds DNA antibodies. Of 34 patients lacking anti-ds DNA antibodies, 16 (47.1%) were shown antinucleosome antibodies. Activity of antinucleosome antibodies was significantly correlated with the SLEDAI scores and inversedly correlated with the C3 levels but not with the C4 levels. CONCLUSION: Antinucleosome antibodies could be one of the earliest and most sensitive markers in diagnosis of SLE, particularly in anti-dsDNA antibodies-negative patients. More importantly, antinucleosome antibodies is correlated with clinical activities and C3 levels.
OBJECTIVE: To examine the correlations between antinucleosome antibodies and anti-double-stranded (ds) DNA antibodies, complement (C) 3 and 4 levels, and clinical activities in SLEpatients. METHODS: Antinucleosome antibodies and anti-dsDNA antibodies were detected by enzyme-linked immunosorbent assays (ELISA). The levels of C3 and C4 were measured by nephelometry. Clinical activities were determined by SLE Disease Activity Index (SLEDAI). RESULTS: Of 65 SLEpatients, the prevalence of antinucleosome antibodies were higher than anti-ds DNA antibodies (52.3 vs 36.9%, respectively, p < 0.05). Similar results were obtained in 45 active SLEpatients, 64.4% for antinucleosome antibodies and 46.7% for anti-ds DNA antibodies. Of 34 patients lacking anti-ds DNA antibodies, 16 (47.1%) were shown antinucleosome antibodies. Activity of antinucleosome antibodies was significantly correlated with the SLEDAI scores and inversedly correlated with the C3 levels but not with the C4 levels. CONCLUSION: Antinucleosome antibodies could be one of the earliest and most sensitive markers in diagnosis of SLE, particularly in anti-dsDNA antibodies-negative patients. More importantly, antinucleosome antibodies is correlated with clinical activities and C3 levels.
Authors: J F Carvalho; V S T Viana; E F Borba; A P do Nascimento; E P Leon; L A Testagrossa; R T Barros; E Bonfá Journal: Clin Rheumatol Date: 2008-06-04 Impact factor: 2.980
Authors: Scott A Jenks; Elise M Palmer; Elides Y Marin; Louise Hartson; Asiya Seema Chida; Christopher Richardson; Ignacio Sanz Journal: Arthritis Rheum Date: 2013-12
Authors: Peter Birner; Susanne Heider; Peter Petzelbauer; Peter Wolf; Christoph Kornauth; Madeleine Kuroll; Olaf Merkel; Günter Steiner; Tadamitsu Kishimoto; Stefan Rose-John; Afschin Soleiman; Richard Moriggl; Lukas Kenner Journal: Exp Dermatol Date: 2016-02-13 Impact factor: 3.960